In addition, hyperactive EZH2 mutations are reported to control cell growth and metastasis through silencing of distinct tumor suppressors, such as DCK, AMD1, and WDR19, in cutaneous melanoma [46]. This evidence concerns the gene DCK and cutaneous melanoma.